Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Publications (selected)

Jahn A#, Rump A#, Widmann TJ#, Heining C, Horak P, Hutter B, Paramasivam N, Uhrig S, Gieldon L, Drukewitz S, Kübler A, Bermudez M, Hackmann K, Porrmann J, Wagner J, Arlt M, Franke M, Fischer J, Kowalzyk Z, William D, Weth V, Oster S, Fröhlich M, Hüllein J, Valle González C, Kreutzfeldt S, Mock A, Heilig CE, Lipka DB, Möhrmann L, Hanf D, Teleanu V, Allgäuer M, Ruhnke L, Kutz O, Knurr A, Laßmann A, Endris V, Neumann O, Penzel R, Beck K, Richter D, Winter U, Wolf S, Pfütze K, Geörg C, Meißburger B, Buchhalter I, Augustin M, Aulitzky WE, Hohenberger P, Kroiss M, Schirmacher P, Schlenk RF, Keilholz U, Klauschen F, Folprecht G, Bauer S, Siveke JT, Brandts CH, Kindler T, Boerries M, Illert AL, von Bubnoff N, Jost PJ, Metzeler KH, Bitzer M, Schulze-Osthoff K, von Kalle C, Brors B, Stenzinger A, Weichert W, Hübschmann D, Fröhling S§, Glimm H§, Schröck E§,* & Klink B§. (2022). Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers. Ann Oncol, doi:10.1016/j.annonc.2022.07.008

Möhrmann L#, Werner M#, Oleś M#, Mock A#, Uhrig S#, Jahn A, Kreutzfeldt S, Fröhlich M, Hutter B, Paramasivam N, Richter D, Beck K, Winter U, Pfütze K, Heilig CE, Teleanu V, Lipka DB, Zapatka M, Hanf D, List C, Allgäuer M, Penzel R, Rüter G, Jelas I, Hamacher R, Falkenhorst J, Wagner S, Brandts CH, Boerries M, Illert AL, Metzeler KH, Westphalen CB, Desuki A, Kindler T, Folprecht G, Weichert W, Brors B, Stenzinger A, Schröck E, Hübschmann D, Horak P, Heining C§, Fröhling S§ & Glimm H§,*. (2022). Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity. Nat Commun, 13(1), 4485. doi:10.1038/s41467-022-31866-4

Dieter SM*, Lovecchio D, Pataskar A, Zowada MK, Körner PR, Khalizieva A, van Tellingen O, Jäger D, Glimm H & Agami R*. (2022). Suppression of heparan sulfation re-sensitizes YAP1-driven melanoma to MAPK pathway inhibitors. Oncogene, 41(32), 3953-3968. doi:10.1038/s41388-022-02400-z

Dieter SM*, Siegl C, Codó PL, Huerta M, Ostermann-Parucha AL, Schulz E, Zowada MK, Martin S, Laaber K, Nowrouzi A, Blatter M, Kreth S, Westermann F, Benner A, Uhrig U, Putzker K, Lewis J, Haegebarth A, Mumberg D, Holton SJ, Weiske J, Toepper LM, Scheib U, Siemeister G, Ball CR, Kuster B, Stoehr G, Hahne H, Johannes S, Lange M, Herbst F & Glimm H*. (2021). Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer. Cell Rep, 36(3), 109394. doi:10.1016/j.celrep.2021.109394

Horak P#, Heining C#, Kreutzfeldt S#, Hutter B#, Mock A, Hüllein J, Fröhlich M, Uhrig S, Jahn A, Rump A, Gieldon L, Möhrmann L, Hanf D, Teleanu V, Heilig CE, Lipka DB, Allgäuer M, Ruhnke L, Laßmann A, Endris V, Neumann O, Penzel R, Beck K, Richter D, Winter U, Wolf S, Pfütze K, Geörg C, Meißburger B, Buchhalter I, Augustin M, Aulitzky WE, Hohenberger P, Kroiss M, Schirmacher P, Schlenk RF, Keilholz U, Klauschen F, Folprecht G, Bauer S, Siveke JT, Brandts CH, Kindler T, Boerries M, Illert AL, von Bubnoff N, Jost PJ, Spiekermann K, Bitzer M, Schulze-Osthoff K, von Kalle C, Klink B, Brors B, Stenzinger A, Schröck E, Hübschmann D, Weichert W, Glimm H§,* & Fröhling S§,*. (2021). Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. Cancer Discov, 11(11), 2780-2795. doi:10.1158/2159-8290.Cd-21-0126

Li L#, Ugalde AP#, Scheele C, Dieter SM, Nagel R, Ma J, Pataskar A, Korkmaz G, Elkon R, Chien MP, You L, Su PR, Bleijerveld OB, Altelaar M, Momchev L, Manber Z, Han R, van Breugel PC, Lopes R, Ten Dijke P, van Rheenen J & Agami R*. (2021). A comprehensive enhancer screen identifies TRAM2 as a key and novel mediator of YAP oncogenesis. Genome Biol, 22(1), 54. doi:10.1186/s13059-021-02272-8

Horak P*, Uhrig S, Witzel M, Gil-Farina I, Hutter B, Rath T, Gieldon L, Balasubramanian GP, Pastor X, Heilig CE, Richter D, Schröck E, Ball CR, Brors B, Braun CJ, Albert MH, Scholl C, von Kalle C, Schmidt M, Fröhling S, Klein C & Glimm H*. (2020). Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia. Leukemia, 34(10), 2785-2789. doi:10.1038/s41375-020-0779-z

Möhrmann L#, Zowada MK#, Strakerjahn H, Siegl C, Kopp-Schneider A, Krunic D, Strunk D, Schneider M, Kriegsmann M, Kriegsmann K, Herbst F, Ball CR, Glimm H* & Dieter SM*. (2020). A perivascular niche in the bone marrow hosts quiescent and proliferating tumorigenic colorectal cancer cells. Int J Cancer, 147(2), 519-531. doi:10.1002/ijc.32933

Ronellenfitsch MW*, Harter PN, Kirchner M, Heining C, Hutter B, Gieldon L, Schittenhelm J, Schuhmann MU, Tatagiba M, Marquardt G, Wagner M, Endris V, Brandts CH, Mautner VF, Schröck E, Weichert W, Brors B, von Deimling A, Mittelbronn M, Steinbach JP§, Reuss DE§, Glimm H§, Stenzinger A§ & Fröhling S§. (2020). Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. J Clin Invest, 130(5), 2488-2495. doi:10.1172/jci130787

Wünsche P#, Eckert ESP#, Holland-Letz T, Paruzynski A, Hotz-Wagenblatt A, Fronza R, Rath T, Gil-Farina I, Schmidt M, von Kalle C, Klein C, Ball CR, Herbst F§ & Glimm H§,*. (2018). Mapping Active Gene-Regulatory Regions in Human Repopulating Long-Term HSCs. Cell Stem Cell, 23(1), 132-146.e139. doi:10.1016/j.stem.2018.06.003

Bormann F, Rodríguez-Paredes M, Lasitschka F, Edelmann D, Musch T, Benner A, Bergman Y, Dieter SM, Ball CR, Glimm H, Linhart HG & Lyko F*. (2018). Cell-of-Origin DNA Methylation Signatures Are Maintained during Colorectal Carcinogenesis. Cell Rep, 23(11), 3407-3418. doi:10.1016/j.celrep.2018.05.045

Heining C#, Horak P#, Uhrig S#, Codo PL, Klink B, Hutter B, Fröhlich M, Bonekamp D, Richter D, Steiger K, Penzel R, Endris V, Ehrenberg KR, Frank S, Kleinheinz K, Toprak UH, Schlesner M, Mandal R, Schulz L, Lambertz H, Fetscher S, Bitzer M, Malek NP, Horger M, Giese NA, Strobel O, Hackert T, Springfeld C, Feuerbach L, Bergmann F, Schröck E, von Kalle C, Weichert W, Scholl C, Ball CR, Stenzinger A, Brors B, Fröhling S§,* & Glimm H§,*. (2018). NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. Cancer Discov, 8(9), 1087-1095. doi:10.1158/2159-8290.Cd-18-0036

Giessler KM#, Kleinheinz K#, Huebschmann D, Balasubramanian GP, Dubash TD, Dieter SM, Siegl C, Herbst F, Weber S, Hoffmann CM, Fronza R, Buchhalter I, Paramasivam N, Eils R, Schmidt M, von Kalle C, Schneider M, Ulrich A, Scholl C, Fröhling S, Weichert W, Brors B, Schlesner M, Ball CR§ & Glimm H§,*. (2017). Genetic subclone architecture of tumor clone-initiating cells in colorectal cancer. J Exp Med, 214(7), 2073-2088. doi:10.1084/jem.20162017

Dieter SM, Glimm H* & Ball CR. (2017). Colorectal cancer-initiating cells caught in the act. EMBO Mol Med, 9(7), 856-858. doi:10.15252/emmm.201707858

Ball CR, Oppel F, Ehrenberg KR, Dubash TD, Dieter SM, Hoffmann CM, Abel U, Herbst F, Koch M, Werner J, Bergmann F, Ishaque N, Schmidt M, von Kalle C, Scholl C, Fröhling S, Brors B, Weichert W, Weitz J & Glimm H*. (2017). Succession of transiently active tumor-initiating cell clones in human pancreatic cancer xenografts. EMBO Mol Med, 9(7), 918-932. doi:10.15252/emmm.201607354

Dieter SM#, Giessler KM#, Kriegsmann M, Dubash TD, Möhrmann L, Schulz ER, Siegl C, Weber S, Strakerjahn H, Oberlack A, Heger U, Gao J, Hartinger EM, Oppel F, Hoffmann CM, Ha N, Brors B, Lasitschka F, Ulrich A, Strobel O, Schmidt M, von Kalle C, Schneider M, Weichert W, Ehrenberg KR, Glimm H§ & Ball CR§,*. (2017). Patient-derived xenografts of gastrointestinal cancers are susceptible to rapid and delayed B-lymphoproliferation. Int J Cancer, 140(6), 1356-1363. doi:10.1002/ijc.30561

Weischenfeldt J#, Dubash T#, Drainas AP#, Mardin BR, Chen Y, Stütz AM, Waszak SM, Bosco G, Halvorsen AR, Raeder B, Efthymiopoulos T, Erkek S, Siegl C, Brenner H, Brustugun OT, Dieter SM, Northcott PA, Petersen I, Pfister SM, Schneider M, Solberg SK, Thunissen E, Weichert W, Zichner T, Thomas R, Peifer M, Helland A, Ball CR, Jechlinger M, Sotillo R, Glimm H* & Korbel JO*. (2017). Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. Nat Genet, 49(1), 65-74. doi:10.1038/ng.3722

Dieter SM#, Heining C#, Agaimy A, Huebschmann D, Bonekamp D, Hutter B, Ehrenberg KR, Fröhlich M, Schlesner M, Scholl C, Schlemmer HP, Wolf S, Mavratzas A, Jung CS, Gröschel S, von Kalle C, Eils R, Brors B, Penzel R, Kriegsmann M, Reuss DE, Schirmacher P, Stenzinger A, Federspil PA, Weichert W§, Glimm H§ & Fröhling S§,*. (2017). Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma. Ann Oncol, 28(1), 142-148. doi:10.1093/annonc/mdw446

Kaeppel C#, Beattie SG#, Fronza R#, van Logtenstein R, Salmon F, Schmidt S, Wolf S, Nowrouzi A, Glimm H, von Kalle C, Petry H, Gaudet D & Schmidt M*. (2013). A largely random AAV integration profile after LPLD gene therapy. Nat Med, 19(7), 889-891. doi:10.1038/nm.3230

Dietrich S#, Glimm H#, Andrulis M, von Kalle C, Ho AD & Zenz T*. (2012). BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med, 366(21), 2038-2040. doi:10.1056/NEJMc1202124

Dieter SM#, Ball CR#, Hoffmann CM#, Nowrouzi A, Herbst F, Zavidij O, Abel U, Arens A, Weichert W, Brand K, Koch M, Weitz J, Schmidt M, von Kalle C* & Glimm H*. (2011). Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell, 9(4), 357-365. doi:10.1016/j.stem.2011.08.010

Boztug K, Schmidt M, Schwarzer A, Banerjee PP, Díez IA, Dewey RA, Böhm M, Nowrouzi A, Ball CR, Glimm H, Naundorf S, Kühlcke K, Blasczyk R, Kondratenko I, Maródi L, Orange JS, von Kalle C & Klein C*. (2010). Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med, 363(20), 1918-1927. doi:10.1056/NEJMoa1003548

Paruzynski A#, Arens A#, Gabriel R#, Bartholomae CC#, Scholz S, Wang W, Wolf S, Glimm H, Schmidt M* & von Kalle C. (2010). Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. Nat Protoc, 5(8), 1379-1395. doi:10.1038/nprot.2010.87

Gabriel R#, Eckenberg R#, Paruzynski A#, Bartholomae CC#, Nowrouzi A, Arens A, Howe SJ, Recchia A, Cattoglio C, Wang W, Faber K, Schwarzwaelder K, Kirsten R, Deichmann A, Ball CR, Balaggan KS, Yáñez-Muñoz RJ, Ali RR, Gaspar HB, Biasco L, Aiuti A, Cesana D, Montini E, Naldini L, Cohen-Haguenauer O, Mavilio F, Thrasher AJ, Glimm H, von Kalle C*, Saurin W§ & Schmidt M§. (2009). Comprehensive genomic access to vector integration in clinical gene therapy. Nat Med, 15(12), 1431-1436. doi:10.1038/nm.2057

# Shared first authorship.
Shared second authorship.
§ Shared senior authorship.
* Corresponding authorship.


to top
powered by webEdition CMS